Insmed initiates three Phase 3 trials of TPIP for pulmonary diseases

By Public Technologies
  • Insmed will feature its four-study Phase 3 PALM program for treprostinil palmitil inhalation powder at CHEST 2026.
  • Three trials have begun; the fourth, PALM-IPF, is expected to start in the first half of 2027.
  • The program aims to enroll more than 2,000 patients to evaluate once-daily treatment for pulmonary hypertension and fibrotic lung diseases.
  • Earlier Phase 2 studies yielded clinically meaningful efficacy and safety findings in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
  • The Phase 3 trials will assess whether treatment improves exercise capacity or preserves lung function across the targeted diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610150700PR_NEWS_USPR_____NY72509) on October 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.